ESOPHAGEAL SQUAMOUS CELL CARCINOMA

This study is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced esophageal cancer that has returned or spread after their first treatment failed. It will involve about 497 adults whose cancer worsened despite prior immunot…

This early-stage clinical trial is testing a new experimental drug called RO7247669 in people with advanced solid tumors that have spread. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. The …

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

This early-stage study is testing a new drug called MCLA-129, which is designed to attack cancer cells by blocking two different growth signals at once. It is for adults with advanced lung, stomach, head/neck, or other solid tumors that have stopped responding to standard treatme…

This study is testing whether adding two immunotherapy drugs (nivolumab and cetuximab) to standard chemotherapy and radiation before surgery helps people with a specific type of advanced esophageal cancer. The goal is to see if this combination can shrink or eliminate the tumor m…

This large, late-stage study is testing whether adding a new drug called tiragolumab to an existing immunotherapy (atezolizumab) can better control advanced esophageal cancer that cannot be surgically removed. The trial involves 760 people whose cancer did not worsen after initia…

This early-stage trial aimed to test the safety and initial effectiveness of a new drug called S095033 when combined with standard chemotherapy (paclitaxel) for people with advanced esophageal cancer that had stopped responding to previous treatments. The study was designed to fi…

This large, late-stage study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be surgically removed. About 640 patients worldwide will receive either the new combination or …

This study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery is safe and effective for people with a type of esophageal cancer that can be removed by surgery. The goal is to see if this combination treatment can better shri…

This study is testing whether a powerful combination of treatments can shrink or eliminate tumors before surgery for esophageal and gastroesophageal junction cancers. Patients receive standard chemotherapy and radiation alongside an immunotherapy drug (pembrolizumab), followed by…

This study is testing whether adding an experimental drug called LBL-007 to a standard immunotherapy and chemotherapy combination works better for people with advanced esophageal cancer that cannot be removed by surgery. It will involve about 118 participants who have not yet rec…

This study is testing whether adding two immunotherapy drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery helps patients with a type of esophageal cancer. The goal is to see if this combination can completely eliminate the cancer in the removed tissue an…

This study is testing if adding an immunotherapy drug (tislelizumab) to standard chemotherapy helps people with a specific type of esophageal cancer that is at high risk of returning. It involves 80 participants whose cancer did not fully disappear after initial chemo and radiati…

This study is testing whether adding a drug called apatinib to standard cancer treatment helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will be randomly assigned to receive the standard treatment alone or the standard treatm…